PAPAIJV
PCRX icon

Paragon Associates & Paragon Associates II Joint Venture’s Pacira BioSciences PCRX Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,000
Closed -$153K – 17
2023
Q3 		$153K Buy
+5,000
New +$180K 0.5% 10

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's PCRX Position: Q4 2023 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Pacira BioSciences (PCRX) in Q4 2023, closing a stake of 5,000 shares — an estimated $153K sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in PCRX in Q3 2023 and held it in 1 quarter. The position peaked at $153K in Q3 2023. 261 funds tracked by Wall St. Rank hold PCRX as of Q4 2023.

  • Paragon Associates & Paragon Associates II Joint Venture reported no remaining Pacira BioSciences position as of Q4 2023 after selling out during the quarter.
  • Paragon Associates & Paragon Associates II Joint Venture sold 5,000 Pacira BioSciences shares in Q4 2023, an estimated $153K.
  • Paragon Associates & Paragon Associates II Joint Venture first reported a position in Pacira BioSciences in Q3 2023 and held it in 1 quarter.
  • Paragon Associates & Paragon Associates II Joint Venture's Pacira BioSciences position peaked at $153K in Q3 2023.
  • 261 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2023.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q4 2023, filed 14 Feb 2024.